Methods, uses and compositions of Tie2 agonists
The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof.
1. A method of treating an animal infected with influenza or with a bacterial superinfection associated with influenza comprising administering a multimeric form of Tie2 binding peptide monomers to the animal in need thereof; wherein each peptide monomer comprises:
(i) a T7 peptide (SEQ ID NO:1) or a T7 modified peptide (SEQ ID NO:2),
(ii) a GA3 peptide (SEQ ID NO:3) or a GA3 modified peptide (SEQ ID NO:4),
(iii) a T4 peptide (SEQ ID NO:9) or a T4 modified peptide (SEQ ID NO:10);
(iv) a T6 peptide (SEQ ID NO:7) or a T8 modified peptide (SEQ ID NO:8); or
(v) a T8 peptide (SEQ ID NO:5) or a T8 modified peptide (SEQ ID NO:6);
wherein the Tie2 binding peptide monomers are multimerized via a linking moiety, spacer and/or multimerizing agent; and wherein the animal is human and the influenza is human influenza.
2. The method of claim 1 , further comprising administering an antiviral agent concurrently or sequentially.
3. The method of claim 2 , wherein the antiviral agent is amantadine, rimantadine, zanamivir, peramivir, viramidine, ribavirin or oseltamivir.
4. The method of claim 1 , wherein the Tie2 binding peptide monomer comprises a T7 peptide as shown in the amino acid sequences of SEQ ID NOs: 1 or 2 or a GA3 peptide as shown in the amino acid sequences of SE Q ID NOs: 3 or 4.
5. The method of claim 1 , wherein the Tie2 binding peptide monomer comprises a peptide selected from the group consisting of a T4 peptide, a T6 peptide and a T8 peptide as shown in the amino acid sequences of SEQ ID NOs: 5-10.
6. The method of claim 1 , wherein the multimeric form is a dimer, comprising: (a) a first peptide chain; (b) a second peptide chain; and (c) a linking moiety connecting said first and second peptide chains.
7. The method of claim 6 , wherein the first peptide chain is a T7 peptide (SEQ ID NOs: 1 or 2) and/or the second peptide chain is a T7 peptide (SEC) ID NOs: 1 or 2).
8. The method of claim 6 , wherein the linking moiety comprises one or more polyethylene glycol polymers covalently bound to the first peptide chain and the second peptide chain.
9. The method of claim 1 , wherein the multimeric form comprises a peptide tetramer, comprising: (a) a first peptide chain; (b) a second peptide chain; (c) a third peptide chain; (d) a fourth peptide chain; and (e) a linking moiety connecting said first, second, third and fourth peptide chains.
10. The method of claim 9 , wherein the first, second, third and fourth peptide chains are T7 peptides (SEQ ID NOs: 1 or 2).
11. The method of claim 9 , wherein the linking moiety comprises one or more branched polyethylene glycol (PEG) polymers covalently bound to the first, second, third and fourth peptide chains, the PEG having a molecular weight in a range of about 3,000 Daltons to about 20,000 Daltons.
12. The method of claim 9 , wherein the first, second, third and fourth peptide chains are T7 peptides (SEQ ID NOs: 1 or 2) and the linking moiety is PEG, the PEG having a molecular weight of about 10,000 Daltons.
13. The method sf claim 1 , for treating a bacterial superinfection associated with human influenza.
14. The method of claim 1 , wherein the multimeric form of Tie2 binding peptide monomers is administered to the human at least 24 hours post-infection.
15. The method of claim 1 , wherein the multimeric form of Tie2 binding peptide monomers is administered to the human at least 48 hours post-infection.
16. The method of claim 1 , wherein the multimeric form of Tie2 binding peptide monomers is administered to the human at least 72 hours post-infection.
17. A composition comprising (a) a multimeric form of Tie2 binding peptide monomers and (b) an antiviral agent; wherein each peptide monomer comprises:
(i) a T7 peptide (SEQ ID NO:1) or a T7 modified peptide (SEQ ID NO: 2);
(ii) a GA3 peptide (SEQ ID NO:3) or a GA3 modified peptide (SEQ ID NO:4);
(iii) a T4 peptide (SEQ ID NO:9) or a T4 modified peptide (SEQ ID NO:10);
(iv) a T6 peptide (SEQ ID NO:7) or a T6 modified peptide (SEQ ID NO:8); or
(v) a T8 peptide (SEQ ID NO:5) or a T8 modified peptide (SEQ ID NO:6);
and wherein the Tie2 binding peptide monomers are muItimerized via a linking moiety, spacer and/or multimerizing agent.
18. A kit comprising (a) a multimeric form of Tie2 binding peptide monomers, (b) an antiviral agent and (c) instructions for use of the kit for treating an animal or cell infected with influenza and/or for treating a bacterial superinfection in an animal or cell infected with influenza; wherein each peptide monomer comprises:
(i) a T7 peptide (SEQ ID NO:1) or a T7 modified peptide (SEQ ID NO:2);
(ii) a GA3 peptide (SEQ ID NO:3) or a GA3 modified peptide (SEQ ID NO:4);
(iii) a T4 peptide (SEQ ID NO:9) or a T4 modified peptide (SEQ ID NO:10);
(iv) a T6 peptide (SEQ ID NO:7) or a T6 modified peptide (SEQ ID NO:8); or
(v) a T8 peptide (SEQ ID NO:5) or a T8 modified peptide (SEQ ID NO:6);
and wherein the Tie2 binding peptide monomers are multimerized via a linking moiety, spacer and/or multimerizing agent.
19. The kit of claim 18 , wherein the antiviral agent is amantadine, rimantadine, zanamivir, peramivir, viramidine, ribavirin or oseltamivir.
20. The kit of claim 18 , wherein the Tie2 binding peptide monomer comprises a T7 peptide as shown in the amino acid sequences of SEQ ID NOs: 1 or 2 or comprises a GA3 peptide as shown in the amino acid sequences of SEQ ID NOs: 3 or 4.
21. The kit of claim 18 , wherein the Tie2 binding peptide monomer comprises a peptide selected from the a group consisting of a T4 peptide, a T6 peptide and a T8 peptide as shown in the amino acid sequences of SEQ ID NOs:5-10.
22. The kit of claim 18 , wherein the multimeric form is a dimer, comprising: (a) a first peptide chain; (b) a second peptide chain; and (c) a linking moiety connecting said first and second peptide chains.
23. The kit of claim 22 , wherein the first peptide chain is a T7 peptide (SEQ ID NOs: 1 or 2) and/or the second peptide chain is a T7 peptide.
24. The kit of claim 22 , wherein the linking moiety comprises one or more polyethylene glycol (PEG) polymers covalently bound to the first peptide chain and the second peptide chain.
25. The kit of claim 18 , wherein the multimeric form comprises a peptide tetramer, comprising: (a) a first peptide chain; (b) a second peptide chain; (c) a third peptide chain; (d) a fourth peptide chain; and (e) a linking moiety connecting said first, second, third and fourth peptide chains.
26. The kit of claim 25 , wherein the first, second, third and fourth peptide chains are T7 peptides (SE Q ID NOs: 1 or 2).
27. The kit of claim 26 , wherein the sinking moiety is PEG, the PEG having a molecular weight of about 10,000 Daltons.
28. The kit of claim 25 , wherein the linking moiety comprises one or more branched polyethylene glycol (PEG) polymers covalently bound to the first, second, third and fourth peptide chains, the PEG having a molecular weight in a range of about 3,000 Daltons to about 20,000 Daltons.